List of Excipients in Branded Drug ZAFEMY

Generic Drugs Containing ZAFEMY

Company	Ingredient	NDC	Excipient
AvKARE	norelgestromin and ethinyl estradiol	42291-930	CROSPOVIDONE
AvKARE	norelgestromin and ethinyl estradiol	42291-930	DIPROPYLENE GLYCOL
AvKARE	norelgestromin and ethinyl estradiol	42291-930	OLEYL ALCOHOL
AvKARE	norelgestromin and ethinyl estradiol	42291-930	POLYBUTENE

What are the Most Frequently-Used Excipients in ZAFEMY?

# Of NDCs	Excipient
3	CROSPOVIDONE
3	DIPROPYLENE GLYCOL
3	OLEYL ALCOHOL
3	POLYBUTENE

ZAFEMY Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

ZAFEMY is a norelgestromin/ethinyl estradiol transdermal contraceptive system with an established active pharmaceutical ingredient profile and limited traditional patent protection. Its commercial opportunity is concentrated in excipient and delivery-system improvements: stronger adhesion, lower skin irritation, controlled drug release, improved wear performance, and differentiated packaging.

The product is a generic-equivalent version of the Xulane contraceptive patch. ZAFEMY delivers approximately 150 mcg of norelgestromin and 35 mcg of ethinyl estradiol per day for seven days through a transdermal matrix system. Its labeled inactive ingredients include polyisobutylene, crospovidone, and lauryl lactate, with polyester backing and release-liner components.[1]

What is ZAFEMY and how does its transdermal system work?

ZAFEMY is a once-weekly hormonal contraceptive patch. It contains the progestin norelgestromin and the estrogen ethinyl estradiol. The patch is applied weekly for three consecutive weeks, followed by one patch-free week.[1]

ZAFEMY composition and delivery profile

Attribute	ZAFEMY profile
Active ingredients	Norelgestromin and ethinyl estradiol
Nominal content	6 mg norelgestromin and 0.6 mg ethinyl estradiol per system
Daily delivery	Approximately 150 mcg norelgestromin and 35 mcg ethinyl estradiol
Dosage form	Once-weekly transdermal system
Primary route	Transdermal
Product category	Combined hormonal contraceptive
Reference product	Xulane
Core excipients	Polyisobutylene, crospovidone, lauryl lactate
Structural materials	Polyester backing and release liner
Prescription status	FDA-approved prescription product
Biosimilar exposure	None; ZAFEMY is a small-molecule combination product

The drug layer uses an adhesive matrix rather than a conventional reservoir system. The matrix must simultaneously provide drug solubilization, skin contact, dose control, mechanical integrity, and acceptable removal characteristics.

What excipients are used in ZAFEMY?

ZAFEMY uses a pressure-sensitive adhesive matrix based primarily on polyisobutylene. Crospovidone and lauryl lactate support drug incorporation and transdermal delivery. The patch also includes non-drug structural components that affect shelf life, adhesion, moisture protection, and user handling.[1]

Polyisobutylene

Polyisobutylene is the principal adhesive component. Its molecular weight distribution, tack, cohesion, and compatibility with the hormones influence:

• Initial skin adhesion
• Seven-day wear performance
• Residue after removal
• Cold-temperature adhesion
• Resistance to edge lift
• Drug diffusion through the matrix
• Skin irritation and sensitization risk

Polyisobutylene is commercially attractive because it is established in transdermal systems and can be adjusted through polymer grade, blending, and concentration. The key development constraint is balance. Higher tack can improve retention but can increase residue, discomfort, and skin trauma. Higher cohesion can reduce residue but may compromise conformability.

Crospovidone

Crospovidone is used in the adhesive drug matrix. In a transdermal system, its role is not identical to its role as a tablet disintegrant. It can influence drug dispersion, matrix microstructure, moisture behavior, and release kinetics.

Potential development variables include particle size, porosity, surface area, loading level, and compatibility with the hormone combination. Crospovidone selection can affect content uniformity and the tendency of the active ingredients to crystallize during storage.

Lauryl lactate

Lauryl lactate functions as an emollient and penetration-enhancing excipient. It can improve skin contact and modify drug partitioning into the stratum corneum. It also affects the softness and handling properties of the adhesive matrix.

Lauryl lactate creates a formulation tradeoff. Increased penetration may improve delivery consistency, but excessive enhancement can increase local exposure, skin irritation, or variability between patients.

Backing and release-liner materials

The polyester backing protects the drug layer and controls exposure to external moisture and mechanical stress. The release liner protects the adhesive before application and must peel cleanly without removing drug matrix or damaging the patch.

Packaging is part of the excipient and delivery strategy. A high-barrier pouch can limit solvent loss, oxidation, moisture ingress, and changes in adhesive performance during storage.

What formulation patents protect ZAFEMY?

ZAFEMY's principal commercial protection is based on the approved product formulation, manufacturing controls, trademarks, regulatory approval, and supply-chain execution rather than a clearly differentiated new excipient platform.

Xulane and earlier norelgestromin/ethinyl estradiol patches were developed from transdermal contraceptive technology that dates to the early 2000s. The foundational patent estate for the patch technology has largely reached the end of its ordinary U.S. patent term. The FDA Orange Book should be used for the current, product-specific listing of patents and regulatory exclusivity.[2]

Patent and exclusivity position

Protection category	ZAFEMY position
Active-ingredient composition	Mature, off-patent small molecules
Basic transdermal contraceptive concept	Mature technology; foundational rights largely expired
Current Orange Book protection	No widely recognized blocking patent estate comparable to a newly launched branded product
Regulatory exclusivity	No meaningful new-chemical-entity exclusivity
Formulation differentiation	Potentially protectable through new claims, but vulnerable to obviousness and written-description challenges
Manufacturing process	Potentially protectable if the process produces a measurable product attribute
Device and packaging	May support design and utility claims, but generally provide narrower protection
Biosimilar barrier	Not applicable
Generic substitution	High, subject to FDA therapeutic-equivalence and state substitution rules

A new formulation patent would need to claim more than the use of a known adhesive or penetration enhancer. Stronger candidates would link a defined excipient range or manufacturing condition to a measurable result, such as:

• Seven-day adhesion across temperature and humidity conditions
• Reduced skin irritation
• Lower drug crystallization
• Improved delivery in high-variability skin models
• Reduced residual solvent
• Improved stability at accelerated conditions
• Lower adhesion failure after bathing or exercise
• A defined in vitro-in vivo correlation

Broad claims covering polyisobutylene, crospovidone, or lauryl lactate alone would face substantial prior-art risk.

What excipient strategies could improve ZAFEMY?

The highest-value excipient strategy is to improve the patient experience without changing the clinically established dose. Four technical areas have commercial relevance.

1. Adhesion improvement

Patch detachment is a direct threat to contraceptive efficacy and patient confidence. Development programs can assess:

• Polyisobutylene grade and molecular weight
• Adhesive solids content
• Tack and peel balance
• Edge-seal behavior
• Compatibility with sunscreen, lotion, sweat, and sebum
• Adhesion after showering and exercise
• Performance across different skin types

A new adhesive matrix could be positioned as a next-generation weekly patch if it preserves drug delivery and avoids additional skin reactions.

2. Irritation and sensitization reduction

Transdermal contraceptive patches can cause erythema, pruritus, and application-site reactions. Commercially useful approaches include:

• Lowering aggressive adhesive fractions
• Replacing or reducing penetration enhancer concentration
• Using a less irritating adhesive blend
• Optimizing matrix pH and residual solvent levels
• Reducing drug crystallization at the skin interface
• Designing a patch with improved removal behavior

A formulation that reduces local reactions could improve discontinuation rates, although clinical substantiation would be required.

3. Drug crystallization and stability control

Norelgestromin and ethinyl estradiol must remain uniformly dispersed in the adhesive matrix throughout shelf life. Crystallization can reduce delivery consistency and create visible product defects.

Potential controls include:

• Excipient compatibility screening
• Particle-size control
• Polymer and enhancer ratio optimization
• Water-activity control
• Improved pouch-barrier performance
• Matrix casting and drying-process controls
• Polarized-light and microscopy testing for crystal formation

This area may support both formulation patents and manufacturing know-how. It is also relevant to lifecycle management because process controls can improve batch yield and reduce rejects.

4. Wearability and human-factors improvement

The patch is exposed to repeated mechanical stress, moisture, clothing friction, and skin movement. A smaller or thinner patch could improve acceptability, but dimensional changes may alter drug loading, flux, and adhesion.

Potential product concepts include:

• Smaller-area patch with equivalent delivery
• Transparent or skin-tone backing
• Lower-residue adhesive
• More flexible backing film
• Easier-to-open pouch
• Improved liner removal
• Packaging that protects the patch from curling
• A patch designed for high-humidity environments

These changes may require a supplemental application, a new 505(b)(2) development program, or an ANDA strategy depending on the degree of product difference and the regulatory pathway.

How does ZAFEMY compare with Xulane?

ZAFEMY and Xulane are commercially close products because they use the same active ingredients, weekly administration schedule, and broad delivery concept. The practical distinction is likely to arise from supply reliability, price, formulary access, pharmacy distribution, and post-market performance rather than from the pharmacology.

Commercial factor	ZAFEMY	Xulane
Product type	Generic-equivalent transdermal system	Reference/branded product
Active ingredients	Norelgestromin and ethinyl estradiol	Norelgestromin and ethinyl estradiol
Administration	Weekly patch	Weekly patch
Main competitive lever	Price, availability, contracting, supply	Brand recognition and established prescribing
Patent leverage	Limited	Historical product and formulation rights largely matured
Formulation opportunity	Adhesion, irritation, packaging, stability	Brand lifecycle management and product differentiation
Generic substitution pressure	High	Subject to generic substitution
Biosimilar competition	Not applicable	Not applicable

A meaningful formulation improvement could create a differentiated product, but a cosmetically modified patch would have limited pricing power unless it produces a documented reduction in adhesion failure, skin reactions, or discontinuation.

What regulatory pathway applies to ZAFEMY excipient changes?

ZAFEMY is regulated as a drug-device combination product. The active ingredients are small molecules, but the delivery system determines exposure and product performance.

Likely regulatory routes

Change	Likely regulatory implication
Same excipients and same qualitative composition	Routine ANDA or post-approval change, depending on scope
Quantitative excipient adjustment	Comparative dissolution, adhesion, residual solvent, stability, and possibly clinical data
New adhesive polymer	Likely substantial equivalence and performance evaluation; clinical bridging may be required
New penetration enhancer	Enhanced safety and pharmacokinetic assessment
Smaller patch with same dose	New device and transdermal performance package
New indication or altered BMI claim	Clinical and regulatory program likely required
New package or liner	Container-closure and stability assessment
OTC conversion	Separate FDA switch program and consumer-labeling review

FDA evaluation of a transdermal generic can include adhesion studies, peel and tack testing, in vitro release testing, pharmacokinetics, residual solvent analysis, and product quality comparisons. The ANDA pathway does not provide a simple route for a substantially redesigned patch.

What generic entry risks exist for ZAFEMY?

Generic-entry risk is already material because ZAFEMY competes in a mature market and the underlying active ingredients are off-patent. The principal risks are commercial rather than patent-based.

Paragraph IV challenges

Paragraph IV litigation is less likely to be a major future barrier for ZAFEMY than for a newly launched drug. The relevant risk is that additional manufacturers can challenge any remaining listed patents or develop alternative products using non-infringing formulations.

Potential challengers would focus on:

• Lack of patent infringement
• Invalidity based on obviousness
• Anticipation by earlier transdermal systems
• Insufficient written description
• Lack of enablement
• Differences in adhesive composition
• Alternative backing or liner structures

A non-infringing formulation can avoid a narrow formulation patent if it maintains equivalent delivery through a different excipient combination.

Biosimilar risk

There is no biosimilar risk. ZAFEMY is not a biologic. Competition will come from ANDA applicants, authorized generics, branded alternatives, and other contraceptive methods.

Which companies could challenge the ZAFEMY market?

The market is open to manufacturers with transdermal manufacturing capability, controlled adhesive coating, pouching, and regulatory experience. Potential competitive categories include:

• Generic pharmaceutical companies
• Contract development and manufacturing organizations
• Transdermal technology companies
• Branded contraceptive companies seeking lifecycle products
• Manufacturers of alternative hormonal patches

The principal barrier is not API sourcing. Norelgestromin and ethinyl estradiol are established molecules. The harder capabilities are low-dose content uniformity, solvent control, continuous adhesive coating, die cutting, pouch integrity, and reproducible adhesion testing.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers

A commercial patch manufacturer must control:

1. Uniform dispersion of both hormones.
2. Adhesive viscosity during coating.
3. Drying conditions and residual solvents.
4. Matrix thickness and coat weight.
5. Drug crystallization.
6. Lamination strength.
7. Die-cut dimensional accuracy.
8. Pouch seal integrity.
9. Release-liner performance.
10. Stability under temperature and humidity stress.

The low daily dose increases the importance of content uniformity. Small changes in coat weight or active dispersion can produce clinically relevant differences in delivery.

Intellectual-property barriers

The strongest protectable assets are likely to be narrow and performance-linked. Examples include:

• A defined polyisobutylene molecular-weight distribution
• A specified crospovidone particle-size range
• A lauryl lactate concentration linked to flux and irritation
• A matrix with controlled crystallization
• A multilayer adhesive architecture
• A defined pouch and liner combination
• A process that produces a specific adhesive or release profile

Trade secrets may be more valuable than patents for coating speed, drying temperature, solvent removal, and quality-control specifications.

What commercial opportunities exist for ZAFEMY excipients?

The most credible opportunities are differentiated products rather than simple excipient substitution.

Priority opportunity matrix

Opportunity	Technical value	Regulatory complexity	Commercial potential
Improved seven-day adhesion	High	Moderate	High
Lower skin irritation	High	Moderate to high	High
Smaller patch	High	High	High
Lower-cost adhesive system	Moderate	Moderate	Moderate
Improved pouch and shelf stability	Moderate	Low to moderate	Moderate
Transparent or cosmetic backing	Moderate	Moderate	Moderate
Alternative penetration enhancer	High	High	Moderate to high
Pediatric or adolescent positioning	High	High	Potentially high
BMI-performance improvement	Very high	Very high	High if clinically demonstrated
OTC conversion	High	Very high	Very high, but distant

The largest unmet commercial issue is the product's labeled limitation in people with a body mass index of 30 kg/m² or greater, where effectiveness may be reduced.[1] An excipient or adhesive system that improves delivery consistency in higher-BMI users could create meaningful differentiation, but this would require robust pharmacokinetic and clinical evidence. It could not be supported solely by an in vitro release claim.

What is the revenue exposure and competitive outlook?

ZAFEMY operates in a price-sensitive contraceptive market with competition from oral contraceptives, intrauterine systems, implants, injectables, vaginal rings, and other patches. Its economic value depends on persistence, pharmacy coverage, and reliable weekly adhesion.

Revenue growth is most likely from:

• Winning formulary contracts
• Capturing Xulane substitution
• Reducing out-of-stock events
• Improving adherence and refill persistence
• Expanding access through lower pricing
• Launching a better-tolerated or better-adhering patch
• Licensing a differentiated adhesive or backing technology

A basic copy has limited pricing power. A patch with validated reduction in detachment, irritation, or replacement frequency could command stronger payer and prescriber interest.

Key Takeaways

• ZAFEMY is a norelgestromin/ethinyl estradiol weekly transdermal contraceptive patch.
• Its core excipients are polyisobutylene, crospovidone, and lauryl lactate, supported by polyester backing and release-liner materials.
• The active ingredients and foundational patch technology are mature, limiting the value of broad composition patents.
• The strongest formulation opportunities are improved adhesion, lower irritation, crystallization control, smaller patch size, and better packaging.
• A new formulation patent should connect a defined excipient or process range to a measurable product-performance benefit.
• ZAFEMY has no biosimilar exposure. Future competition is primarily from ANDA applicants and alternative contraceptive products.
• Manufacturing know-how in coating, drying, content uniformity, pouching, and stability may be more valuable than broad excipient claims.
• The highest-value unmet opportunity is a patch with reliable performance in users affected by the current BMI limitation, but that opportunity requires clinical validation.

FAQs

Can ZAFEMY use a different adhesive and remain therapeutically equivalent?

Yes, but the revised product would need to demonstrate comparable drug delivery, adhesion, stability, and safety. A different adhesive may trigger a substantial equivalence assessment beyond routine formulation comparison.

Is lauryl lactate essential to ZAFEMY performance?

It is part of the labeled formulation, but it is not necessarily irreplaceable. Any replacement would need to preserve transdermal flux, adhesion, tolerability, and stability.

Can an excipient supplier patent a better ZAFEMY adhesive?

Yes, if the claims cover a novel and non-obvious composition or process with adequate technical support. Performance-linked claims are more defensible than claims covering a known polymer in a conventional patch.

Would a smaller ZAFEMY patch create a new product opportunity?

Yes. A smaller patch could improve cosmetic acceptability and wearability, but it would require reoptimization of drug loading, flux, adhesive performance, and manufacturing controls.

Can ZAFEMY be converted to an over-the-counter contraceptive?

A switch would require a separate FDA review of consumer self-selection, labeling, safe use without a prescriber, packaging, and post-market risk management. The existing prescription approval does not authorize OTC sale.

References

1. U.S. Food and Drug Administration. (2024). ZAFEMY (norelgestromin and ethinyl estradiol) transdermal system: Prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (2013). Guidance for industry: Transdermal and topical delivery systems-product development and quality considerations.
4. U.S. Food and Drug Administration. (2022). Product-specific guidance for norelgestromin and ethinyl estradiol transdermal system. FDA.